anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Potential subjects aged 6 years to 12 years, 11 months old with DSM 5 ARFID, and weight equal to or between 75 to 88% EBW who are medically stable for outpatient treatment and their families will be recruited through Stanford University, pediatricians, mental health experts, clinics treating EDs, and local parents' groups. Those eligible for the program will be invited to read and sign informed consent forms and complete the baseline assessment. Participants will then be randomized to FBT-ARFID with medical management for 14 sessions provided over 4 months or manualized Non-Specific Care (NSC) with medical management for 4 months. NSC will consist of 14 sessions over 4 months.

There will be 5 major assessment time points: Baseline, 1 month, 2 months, End Of Treatment (4 months), and 6-month post-treatment Follow-Up. Both the child and the parent will complete measures at these time points. In addition, parents will complete short survey assessments after each of the 14 treatment sessions.
FIELD: pharmaceutical industry. SUBSTANCE: invention relates to dry preparation of essentially spherical particles consisting of high-activity substance introduced into biologically compatible polymer with high boiling temperature, this polymer and above-mentioned high-activity substance being admixed under stirring to immiscible homogeneous viscous carrier. Stirring is continued until formation of biologically compatible polymer microbeads and complete introduction of high-activity substance into them are attained. Temperature of this process is not higher than vitrification temperature of polymer. EFFECT: enabled formation of microbeads with load on core material more than 15% and which have no high-activity substance on their surfaces. 16 cl, 10 ex
High frequency TMS will be applied with an eight-shaped coil angled at zero degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1). Twenty four stimulus trains will be provided at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 1200 pulses for approximately 12 minutes, with 90% of resting motor threshold (RMT). After TMS, patients will be submitted to 45 minutes of manual therapy protocol.
The routine exercise care group, that is, the control group, will complete the routine exercise care of patients with acute ischemic stroke after venous hemolytic surgery in accordance with the hospital regulations: From 24 hours after surgery, patients with mild and moderate stroke can be turned over in bed (once every 2 hours), ankle pump exercise (three times a day), and transitional bedside rehabilitation exercise (such as walking around the bed, etc.) after no discomfort.
Initiation of 780G insulin pump. First two weeks run-in-phase in open loop Manual mode, followed by a12 month study phase with advanced hybrid closed loop Auto mode.
Study participants will be asked to complete a series of brief surveys over time about their medical condition. The researchers will also attain primary medical records.The registry is based at UCLA as the IRB of record with collaborating sites at Boston Children's Hospital, Cincinnati Children's Hospital, and Duke University in a partnership with the Bohring-Opitz Syndrome (BOS) Foundation and ASXL-Rare Research Endowment (ARRE). The BOS Foundation and ARRE are non-profit organizations run by families of patients with ASXL-related disorders that are focused on supporting research. The data is co-managed by the researchers and the family groups. Aggregate data from the Registry will be shared with the participants as well as used for publication. The Registry is HIPPA compliant and follows all the IRB requirements regarding securing and managing patient data.
Identically to the experimental intervention, the therapy is provided online within 10 weeks. Also identical to the experimental intervention, the control intervention will adhere to guidelines for patient-centered care. The control group will receive pain neuroscience education in combination with cognition-targeted exercise therapy alone.
Stage V FH, FA, or DA Wilms' tumor: After bilateral conventional surgery (biopsy), patients with FH receive chemotherapy as in stratum 1 (dactinomycin IV weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate IV weeks 1-10, 12, 15, and 18) or 4 (dactinomycin IV weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weeks 1-10, 12, 15, 18, 21, and 24). Patients with FA or DA receive chemotherapy as in stratum 7 (vincristine sulfate VCR IV weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy.
Usual care consisting of Weight management clinic consultation at baseline randomization, 3 and 6 months post randomization in a tertiary setting in KK Hospital. Duration of treatment is 6 months. Qualified pediatrician, trained in screening for causes and medical complications of obesity in children, runs the weight management clinic and review the participant at each visit. Optional physical activity, dietary consultation at each weight management clinic visit.
The mechanical properties of the cornea in corneal ectasia disease undergo a significant reduction, yet the alterations in mechanical properties within distinct corneal regions remain unclear. In this study, we established a rabbit corneal ectasia model by employing collagenase II to degrade the corneal matrix within a central diameter of 6 mm. Optical coherence tomography was employed for the in vivo assessment of corneal morphology (corneal thickness and corneal curvature) one month after operation. Anisotropy and viscoelastic characteristics of corneal tissue were evaluated through biaxial and uniaxial testing, respectively. The results demonstrated a marked decrease in central corneal thickness, with no significant changes observed in corneal curvature. Under different strains, the elastic modulus of the cornea exhibited no significant differences in the up-down and naso-temporal directions between the control and model groups. However, the cornea in the model group displayed a significantly lower elastic modulus compared to the control group. Specifically, the elastic modulus of the central region cornea in the model group was significantly lower than that of the entire cornea within the same group. Moreover, in comparison to the control group, the cornea in the model group exhibited a significant increase in both creep rate and overall deformation rate. The instantaneous modulus and equilibrium modulus were significantly reduced in the model cornea. No significant differences were observed between the entire cornea and the central cornea concerning these parameters. The results indicate that corneal anisotropy remains unchanged in collagenase-induced ectatic cornea. However, a significant reduction in viscoelastic properties is noticed. This study provides valuable insights for investigating changes in corneal mechanical properties within different regions of ectatic corneal disease.
Anlotinib Hydrochloride Combined With Liposomal Doxorubicin Liposomal Doxorubicin 50mg/m2 Day 1 every-3-weeks (Q3W) and Anlotinib 12mg QD po at Day 8-21 Q3W and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.
Family Support Groups will be piloted with families in community and clinical sites. Each pair of facilitators will pilot two groups of 6 families each. Each group is 4 sessions lasting 2 hours each. Each of the sessions incorporates didactic talks, family discussion, and separate breakout groups for adolescents and adults. Family Support intervention incorporates cognitive-behavioral theory of PM+ which underlies evidence-based techniques focused on stress management and behavioral activation. Family support intervention also incorporates resilience theory, which explains family protective processes that can ameliorate the negative consequences of hardships and challenges and enable healing and growth in families.
FIELD: medicine, hematology. SUBSTANCE: invention relates to concentrate of blood coagulation system factor IX concentrate and method of its preparing, namely, to preparing antihemophilic preparations used for treatment of patients with hemophilia of different genesis. Invention relates to the end product that is prothrombin complex showing activity of factor IX 13-20 IU/ml, specific activity 3.1-4.5 IU/mg, containing 0.05-0.07 M glycine as stabilizing agent of factor IX activity and concentration of ions Na +  240-270 mmole/l. Method involves defrosting donor plasma product (cryosupernatant or freshly frozen donor plasma), regulation of its pH value to pH of initial buffer solution 7.2-7.8, dilution with the same buffer up to the protein content 5-6%, centrifugation at 5000-6000 x g for 15-20 min followed by filtration of supernatant. Obtained solution is adsorbed on column with ion-exchange resin DEAE-Toyopearl and the end product is eluted by step gradient at ion strength 200-360 mmole of Na + /l in 0.01-0.02 M tris-buffer solution at pH 7.0- -7.5 containing 0.05-0.07 M glycine and 0.05-0.06 M trisodium citrate. EFFECT: increased activity and yield of end product. 8 cl, 4 ex
BACKGROUND AND AIMS: We aimed to explore the association between coronavirus disease-19 (COVID-19) vaccination and long COVID according to the status of chronic multimobidity.
METHODS: A total of 1913 participants were recruited in the cross-sectional study on the basis of the Survey of Health and Retirement in Europe. COVID-19 vaccination was defined as vaccination within the last 12 months. Chronic multimorbidity was defined as history of 2 + chronic disease. The study outcome was long COVID during the 12-month follow-up. Multivariable logistic models were performed to estimate the influence of chronic multimorbidity on the association of vaccination with long COVID. Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were calculated.
RESULTS: Chronic multimorbidity significantly modified the association of COVID-19 vaccination with long COVID (Pinteraction = 0.024). The rates of study outcome were significantly lower among vaccinated participants in the chronic multimorbidity subgroup, but not in the other subgroup. Multivariable odds ratios (95 % confidence intervals) of study outcome for unvaccination vs. vaccination were 1.494 (1.013-2.203) in those with multimorbidity and 0.915 (0.654-1.280) in those without multimorbidity, respectively. Adding COVID-19 vaccination to a model containing conventional risk factors significantly improved risk reclassification for study outcome among those with chronic multimobidity (continuous NRI was 25.39 % [P = 0.002] and IDI was 0.42 % [P = 0.075]) CONCLUSION: An inverse association of COVID-19 vaccination with long COVID was found among participants with chronic multimorbidity, but not among those without chronic multimorbidity. Chronic multimorbidity might expand the influence of unvaccination on developing long COVID among European aged ≥50 years.
Maternal and paternal caregivers (if present) of participating Karen family. Community health worker interventionists (CHWI) will deliver 7 weeks of home-based intervention with optional post-intervention focus groups to examine the feasibility of the community-based participatory research approach and intervention delivery by CHWIs.
Peripheral intravenous catheterization was performed by the same emergency department nurse in accordance with the procedure. The process took an average of 3 minutes. There was no application to the patients in the control group except for the standard procedure. After the procedure was completed, the pain and satisfaction status of the patients were scored on the VAS by the same nurse.
The invention is suitable for the technical field of genetic engineering, and provides phage chimeric lyase for killing streptococcus suis, the nucleotide sequence of which is shown as SEQ ID NO.1, and the amino acid sequence of which is shown as SEQ ID NO. 2. The invention also provides a preparation method of the phage chimeric lyase, which comprises the following steps: recombinant expression of phage chimeric lyase ClyU and construction of vector; transformation of the expression vector pET-15b-ClyU; expression and purification of phage chimeric lyase ClyU. The invention also provides application of the phage chimeric lyase in inhibiting and killing streptococcus suis. The invention also provides application of the phage chimeric lyase in preparing a pharmaceutical composition for killing streptococcus suis. The phage chimeric lyase capable of effectively killing streptococcus suis is constructed by the gene splicing technology, has strong cracking activity and wider cracking spectrum for streptococcus suis, and can effectively kill streptococcus suis.
Estrogen influences brain development in females at puberty. Environmental and cultural factors interact with the biological effects of estrogen on the brain and consequently on cognition and behavior. Turner syndrome females lack endogenous estrogen as a result of dysgenetic ovaries. Turner syndrome therefore represents a unique, estrogen-deficient model in which to study the biological effects of estrogen on cognition and behavior. The specific aims of this project are to: 1) document further, the cognitive differences between girls with Turner syndrome at ages 5 to adult (less than or equal to age 50) versus age-matched, female controls. 2) to examine the differential effects of continuous estrogen replacement in infancy and in early childhood on cognitive and social function in a unique, previously approved, randomized, double-blind, placebo-controlled, treatment trial (87-CH-0152). Specifically, we hypothesize that estrogen replacement in early childhood will reduce the cognitive deficits of girls with Turner syndrome. In addition, we hypothesize that the degree of socialization ability in these girls will correlate with social-behavioral and social recognition ability. Finally, we hypothesize that earlier (infancy to 8 years) and longer estrogen replacement will result in less impairment of visual-motor ability, visual-spatial ability, socialization ability, and affective competence compared to later (9 to 12 years) estrogen replacement in girls with Turner syndrome.

Children with Turner syndrome and controls will be tested in the Outpatient Departments at the two approved sites of protocol 87-CH-0152; the NIH and Thomas Jefferson University.
Subject will undergo screening procedures, subject will have blood drawn from a vein in your arm to measure subject's Vitamin D level (about 1 tablespoon).If the subject is eligible based on the results of their blood work and the subject agrees to participate in this study, the subject will return to the clinic to begin the study. There will be 4 study visits every 2 months and phone interviews every 2 weeks during the 6 month study. In the beginning (Visit 1) and end of the study (Visit 4), fasting blood samples will be collected for analysis of fasting plasma glucose, %HbAlc (your long-term sugar control over a 3 month period), calcium, insulin, and Vitamin D level. Urine samples will be collected to determine urinary microalbumin-creatinine ratio (early protein loss in the kidneys). Blood pressure will be measured three times with an automatic blood pressure machine. Height and weight will be measured. A medical history questionnaire will be completed by subjects that will include basic demographics, typical dietary intake, smoking and alcohol history, medical history, as well as list of medications and over-the-counter supplements.

At Visit 1 the subject will be randomized (like the toss of a coin) to receive either a sugar pill or a high dose Vitamin D medication, which the subject will take once a week for 8 weeks and then once a month for 4 months. The subject will have a 50:50 chance of receiving one or the other pill. At Visit 2 and Visit 3, the subject will also get blood work to analyze your calcium and Vitamin D level. At each clinic visit, the subject will also have your blood sugar and high blood pressure managed closely by the study investigators, both of who are doctors (one being a primary care doctor and another being an endocrinology/diabetes doctor), according to a standardized preset flowchart.

This means that the doctors in this study will be controlling the subject's blood sugar and blood pressure values closely and may be changing the subject's blood pressure and/or your blood sugar medications during this study depending on what the subject's blood sugar and blood pressure values are. The subject will be instructed not to have their own primary care doctor or diabetes doctor adjust their diabetes or blood pressure as both will be managed closely by the study doctors during the entire 6 month study period. The subject doctors' will be sent a letter notifying of the subject's participation in the study and be instructed not to adjust any of the subject's blood sugar or blood pressure medications during the entire 6 month study as it will be done closely by the study doctors, as clinically indicated. The subject's doctor will be sent letters after each study visit detailing what changes were done, if any, to your blood sugar and blood pressure medication regimen. The subject will be interviewed on the phone every 2 weeks to assess for any medication adverse reactions and treatment compliance.
A microRNA for gene knockdown of the N-methyl-D-aspartate receptor NR1 subunit, comprises a first fragment, a second fragment and a joining fragment. The second fragment is a palindrome with an inverted repeat sequence of the first fragment. The joining fragment composed by bases at random, and the two ends of the joining fragment connect with the first and second fragment, respectively. The first fragment comprises a dicer-cutting site, and a Drosha-cutting site, and between the two sites is a silencing fragment. The silencing fragment is homologous to the RNA sequence of NMDA receptor NR1 subunit. The present invention also discloses the use of the microRNA and a medication to release skin inflammatory pain.
The management of thrombosed external hemorrhoids (TEH) during pregnancy is still under debate because of the fear of potential adverse effects on the fetus. This study aims to compare efficacy and safety of conservative versus surgical treatment of acute TEH in pregnant women. Furthermore, the outcome of two different surgical approaches was evaluated. This is a prospective observational study including a sub-analysis on two randomized groups of pregnant women affected by TEH. The primary outcome measured was the impact of conservative and surgical treatment defined in terms of VAS, clinical patient grading assessment scale (CPGAS) and the SF-12 questionnaire. In a randomized sub-analysis of the surgical treatment, the outcome of local excision (LE) versus thrombectomy (TE) was compared. Fifty-three patients entered the study. Twenty-six patients had conservative treatment and 22 underwent surgery. Within the surgical group, 8 were randomized for TE and 14 for LE. VAS, SF-12 and CPGAS improved in both groups after 3 and 10 days from the treatment. However, physical (PCS) and mental health (MCS) domains of the SF-12 and CPGAS showed a significant difference in favor of surgery on the 10th day (PCS: p < 0.002 and MCS: p = 0.03; CPGAS: p = 0.002). The surgical group showed an earlier significant reduction of pain on the 3rd day (p = 0.0004). In the surgical group, randomization was halted due to ethical concerns arising from a notable difference in the primary end point between subgroups during interim analysis. Specifically, the re-thrombosis rate was 38% (3/8) after TE and 7% (1/14) after LE. No complications occurred for either mothers or fetuses. Both surgical and conservative treatments are safe and effective. However, surgery allows a faster relief of anal pain. Thrombectomy is associated with higher risk of re-thrombosis when compared to local excision (clinicaltrials.gov ID number NCT04588467).
The majority of cognitive-related adverse events were mild to moderate in severity, and they frequently occurred in isolation. Rapid titration rate and higher initial dose were associated with higher incidences of these events. Many of these events contributed to withdrawal from treatment [see ADVERSE REACTIONS, Table 5 and Table 7].

In the original add-on epilepsy controlled trials (using rapid titration such as 100 to 200 mg/day weekly increments), the proportion of patients who experienced one or more cognitive-related adverse events was 42% for 200 mg/day, 41% for 400 mg/day, 52% for 600 mg/day, 56% for 800 and 1000 mg/day, and 14% for placebo. These dose-related adverse reactions began with a similar frequency in the titration or in the maintenance phase, although in some patients the events began during titration and persisted into the maintenance phase. Some patients who experienced one or more cognitive-related adverse events in the titration phase had a dose-related recurrence of these events in the maintenance phase.

In the monotherapy epilepsy controlled trial, the proportion of patients who experienced one or more cognitive-related adverse events was 19% for topiramate 50 mg/day and 26% for 400 mg/day.
PURPOSE:To readily produce a carcinostatic substance, capable of exhibiting carcinostatic property by not only peritoneal but also oral administration in animal experiments and having low toxicity, by extracting Volvariella volvacea with hot water. CONSTITUTION:10-30pts.wt. 0.1M sodium phosphate buffer solution at 7.0 pH containing preferably 0.9% sodium chloride, etc., is added to 1pt.wt. freeze- dried Volvariella volvacea to carry out preliminary extraction at 4-10 deg.C while stirring for a whole dan and night. The unextracted components containing a carcinostatic substance are then separated by filtration or centrifugation to carry out extraction with hot water in an amount of 5-100pts.wt. based on 1pt.wt. Volvariella volvacea at 80-130 deg.C for 10min-20hr 1-10 times. The resultant hot water extract is then collected and concentrated until the extract attains an amount of 1-50pts.wt. based on 1pt.wt. dried raw material. The above-mentioned concentrate is then preferably desalted using a dialysis tube, ultrafiltration, etc., and freeze-dried to afford the aimed substance.
Critical care advancements have allowed clinicians to discover the many functional disabilities that survivors suffer. Recent research has focused on improving the long-term outcomes of critical illness survivors and optimizing their functional recovery. Post-intensive care syndrome (PICS) describes the disability that remains in those surviving critical illness following discharge from the intensive care unit (ICU). This comprises impairment in cognition, neuropsychiatric health, and physical function of the ICU survivor. Consequent to this, the health of family members of the survivor may also be affected adversely, termed PICS-family. PICS is defined as a new or worsening impairment in physical (ICU-acquired neuromuscular weakness), cognitive (thinking and judgment), or mental health status arising after critical illness and persisting beyond discharge from the acute care setting.
Participants will be asked to perform a physical activity program, consisting of cycling and/or running for 6 weeks of at least 150min/week. This at a moderate intensity, which means a slightly increased heart rate and breathing also talking is possible.